July 5, 2017 Share

July Monthly Membership Luncheon

July 13, 2017 @ 11:30 am – 1:30 pm
Princeton Marriot Hotel & Conference Center
100 College Rd E
Princeton, NJ 08540
$50 Members | $75 Future Members
Alice Barfield
(609) 924-1776 x 102

Speaker:  Hervé Hoppenot
Chairman, President & CEO
Incyte Corporation

Topic:  Scientific Innovation is Transforming the World

Learn how Incyte is contributing to the search for a cure for Cancer.

The pace of innovation in many scientific areas is accelerating. In the field of cancer biology, two areas are reaching a point where practical applications are becoming widely available : Targeted therapies based on cancer genetic alterations and Immunotherapies to re-ignite the patient’s immune system to eradicate cancer cells. In both areas, Incyte is at the forefront of the scientific progress and is contributing to making a Cure for Cancer a possibility in the years ahead.

Great companies are built on passion for making the world a better place. Incyte’s internal motto is “Work hard, Stay Calm and Cure Cancer”.  – Herve Hoppenot

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval, and commercialization, which included $11 billion in global sales, the largest oncology pipeline in the industry, and 8000 employees in 50 countries. Mr. Hoppenot joined Novartis in 2003, and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.